Takeda Pharmaceutical Company Limited Stock
Stocks
4502
JP3463000004
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,847.00 JPY | +1.79% |
|
+5.26% | +20.93% |
| 07-28 | SBI Securities Starts Takeda Pharmaceutical at Neutral with 5,400 Yen Price Target | MT |
| 07-27 | China's Innocare says psoriasis oral drug shows 'consistent treatment effect' in late-stage trial | RE |
| Market Cap | 9,336B 56.98B 50.07B 46.73B 42.89B 80.29B 5,458B 82.27B 554B 217B 2,701B 214B 209B | P/E 2027 * |
48.3x | P/E 2028 * | 29.5x |
|---|---|---|---|---|---|
| Enterprise Value | 13,272B 81B 71.17B 66.44B 60.97B 114B 7,758B 117B 788B 308B 3,839B 304B 298B | EV / Sales 2027 * |
2.85x | EV / Sales 2028 * | 2.77x |
| Free-Float |
99.26% | Yield 2027 * |
3.5% | Yield 2028 * | 3.58% |
Last Transcript: Takeda Pharmaceutical Company Limited
| 1 day | +1.79% | ||
| 1 week | +5.26% | ||
| Current month | +13.42% | ||
| 1 month | +14.94% | ||
| 3 months | +10.55% | ||
| 6 months | +15.05% | ||
| Current year | +20.93% |
| 1 week | 5,467 |  | 5,903 |
| 1 month | 5,112 | | 5,903 |
| Current year | 4,710 | | 6,033 |
| 1 year | 4,102 | | 6,033 |
| 3 years | 3,852 | | 6,033 |
| 5 years | 2,993 | | 6,033 |
| 10 years | 2,894.5 | | 6,693 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 2026-06-23 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 2024-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 2022-01-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 2015-05-31 |
Steven Gillis
BRD | Director/Board Member | 73 | 2018-12-31 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 2024-05-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/10/26 | Issuer sale | Director | -1,152 | 0.0001% | ||
| 7/10/26 | Issuer sale | Chairman | -2,152 | 0.0001% | ||
| 7/10/26 | Issuer sale | Chief Financial Officer; Director | -16,619 | 0.0010% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.79% | +5.26% | +35.82% | +35.22% | 56.03B | |
| -0.35% | +4.51% | +59.32% | +167.41% | 1,089B | |
| -0.36% | +4.12% | +58.32% | +58.87% | 643B | |
| +0.98% | +4.82% | +38.86% | +77.51% | 465B | |
| -1.69% | +8.81% | +39.38% | +33.67% | 359B | |
| -0.51% | +3.51% | +36.97% | +42.46% | 303B | |
| +1.50% | +3.40% | +17.71% | +17.41% | 267B | |
| +0.79% | +5.81% | -2.55% | -38.10% | 226B | |
| -0.98% | +6.46% | +28.38% | +66.44% | 212B | |
| -0.31% | +2.85% | +17.35% | +76.06% | 167B | |
| Average | +0.09% | +4.91% | +32.96% | +53.69% | 378.72B | |
| Weighted average by Cap. | -0.12% | +5.11% | +42.40% | +80.77% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,656B 28.42B 24.97B 23.31B 21.39B 40.04B 2,722B 41.03B 276B 108B 1,347B 107B 104B | 4,734B 28.89B 25.38B 23.69B 21.75B 40.71B 2,767B 41.71B 281B 110B 1,369B 108B 106B |
| Net income | 181B 1.1B 970M 905M 831M 1.56B 106B 1.59B 10.73B 4.2B 52.31B 4.14B 4.05B | 310B 1.89B 1.66B 1.55B 1.42B 2.66B 181B 2.73B 18.38B 7.19B 89.55B 7.09B 6.94B |
| Net Debt | 3,936B 24.02B 21.11B 19.7B 18.08B 33.85B 2,301B 34.68B 234B 91.36B 1,139B 90.19B 88.23B | 3,791B 23.14B 20.33B 18.98B 17.42B 32.6B 2,216B 33.41B 225B 88.01B 1,097B 86.87B 84.99B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-29 | JP¥5,847.00 | +1.79% | 5,289,600 |
| 26-07-28 | JP¥5,744.00 | -0.43% | 3,918,100 |
| 26-07-27 | JP¥5,769.00 | +2.14% | 4,647,600 |
| 26-07-24 | JP¥5,648.00 | +2.60% | 3,633,100 |
| 26-07-23 | JP¥5,505.00 | -0.85% | 2,920,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
Select your edition
All financial news and data tailored to specific country editions
